Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to relieve constipation from painkillers

NCT ID NCT01040637

Symptom relief Sponsor: Glycyx Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called TD-1211 in healthy volunteers and people with constipation caused by opioid painkillers. The goal was to see if it is safe and helps with bowel movements. Participants took different doses of TD-1211 or a placebo, and researchers monitored their safety and how well the drug worked.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TD-1211
What this could lead to
If it works, this could lead to a new treatment for opioid-induced constipation, helping people on long-term opioids have more regular bowel movements.
What could go wrong
This is an early phase 1/2 trial with only 102 participants, so results may not apply to everyone. The drug may not work better than a placebo or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

102 people

The number who actually took part.

Start date

Jan 2010

Finished

Oct 2010

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females between 18 and 65 years of age, inclusive * Healthy subjects and subjects with documented OIC on stable opioid regimen * Willingness to stop all laxatives throughout the OIC screening and treatment period Exclusion Criteria: * Any clinically significant finding in healthy subjects * Have participated in another clinical trial of an investigational drug 30 days prior to screening * History of chronic constipation prior to opioid therapy in OIC subjects * Active medical disorders associated with diarrhea or intermittent loose stools in OIC subjects

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opioid-induced constipation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy Opioid induced constipation

Contacts and locations

Locations

  • Clinical Research Unit

    Pasadena, California, 91105, United States

  • Clinical Research Unit

    San Antonio, Texas, 78209, United States

  • Clinical Research Unit

    Salt Lake City, Utah, 84106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.